Novel Therapeutic Potentials of Taxifolin for Obesity-Induced Hepatic Steatosis, Fibrogenesis, and Tumorigenesis

The molecular pathogenesis of nonalcoholic steatohepatitis (NASH) includes a complex interaction of metabolic stress and inflammatory stimuli. Considering the therapeutic goals of NASH, it is important to determine whether the treatment can prevent the progression from NASH to hepatocellular carcinoma. Taxifolin, also known as dihydroquercetin, is a natural bioactive flavonoid with antioxidant and anti-inflammatory properties commonly found in various foods and health supplement products. In this study, we demonstrated that Taxifolin treatment markedly prevented the development of hepatic steatosis, chronic inflammation, and liver fibrosis in a murine model of NASH. Its mechanisms include a direct action on hepatocytes to inhibit lipid accumulation. Taxifolin also increased brown adipose tissue activity and suppressed body weight gain through at least two distinct pathways: direct action on brown adipocytes and indirect action via fibroblast growth factor 21 production in the liver. Notably, the Taxifolin treatment after NASH development could effectively prevent the development of liver tumors. Collectively, this study provides evidence that Taxifolin shows pleiotropic effects for the treatment of the NASH continuum. Our data also provide insight into the novel mechanisms of action of Taxifolin, which has been widely used as a health supplement with high safety.

[1]  E. G. Varlamova,et al.  Cytoprotective Properties of a New Nanocomplex of Selenium with Taxifolin in the Cells of the Cerebral Cortex Exposed to Ischemia/Reoxygenation , 2022, Pharmaceutics.

[2]  Xiaoying Yu,et al.  Effect of Dihydroquercetin on Energy Metabolism in LPS-Induced Inflammatory Mice , 2022, BioMed research international.

[3]  C. Lee,et al.  Extract of Pinus densiflora needles suppresses acute inflammation by regulating inflammatory mediators in RAW264.7 macrophages and mice , 2022, Pharmaceutical biology.

[4]  M. Goltyaev,et al.  Comparative Analysis of the Cytotoxic Effect of a Complex of Selenium Nanoparticles Doped with Sorafenib, “Naked” Selenium Nanoparticles, and Sorafenib on Human Hepatocyte Carcinoma HepG2 Cells , 2022, International journal of molecular sciences.

[5]  F. Yoshizawa,et al.  Antidiabetic Effect of Taxifolin in Cultured L6 Myotubes and Type 2 Diabetic Model KK-Ay/Ta Mice with Hyperglycemia and Hyperuricemia , 2021, Current issues in molecular biology.

[6]  Qing-Feng Zhang,et al.  The anti-obesity and gut microbiota modulating effects of taxifolin in C57BL/6J mice fed with high-fat diet. , 2021, The Journal of the Science of Food and Agriculture.

[7]  Souvik Roy,et al.  Pharmacological basis and new insights of taxifolin: A comprehensive review. , 2021, Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie.

[8]  A. Enomoto,et al.  The sodium-glucose cotransporter-2 inhibitor Tofogliflozin prevents the progression of nonalcoholic steatohepatitis-associated liver tumors in a novel murine model. , 2021, Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie.

[9]  Chuanbo Ding,et al.  Taxifolin, Extracted from Waste Larix olgensis Roots, Attenuates CCl4-Induced Liver Fibrosis by Regulating the PI3K/AKT/mTOR and TGF-β1/Smads Signaling Pathways , 2021, Drug design, development and therapy.

[10]  A. Sanyal,et al.  Therapeutic pipeline in nonalcoholic steatohepatitis , 2021, Nature Reviews Gastroenterology & Hepatology.

[11]  T. Suganami,et al.  Iron-rich Kupffer cells exhibit phenotypic changes during the development of liver fibrosis in NASH , 2021, iScience.

[12]  Chuanbo Ding,et al.  Taxifolin, a novel food, attenuates acute alcohol-induced liver injury in mice through regulating the NF-κB-mediated inflammation and PI3K/Akt signalling pathways , 2021, Pharmaceutical biology.

[13]  H. Kida,et al.  In vitro anti-inflammatory and anti-lipid accumulation properties of taxifolin-rich extract from the Japanese larch, Larix kaempferi , 2020, Heliyon.

[14]  M. Suematsu,et al.  C-type lectin Mincle mediates cell death–triggered inflammation in acute kidney injury , 2020, The Journal of experimental medicine.

[15]  Mingyi Zhao,et al.  Dihydroquercetin Activates AMPK/Nrf2/HO-1 Signaling in Macrophages and Attenuates Inflammation in LPS-Induced Endotoxemic Mice , 2020, Frontiers in Pharmacology.

[16]  M. Ishigami,et al.  Dipeptidyl peptidase-4 inhibition prevents nonalcoholic steatohepatitis–associated liver fibrosis and tumor development in mice independently of its anti-diabetic effects , 2020, Scientific Reports.

[17]  Yu-Shih Lin,et al.  Hepatoprotective Mechanisms of Taxifolin on Carbon Tetrachloride-Induced Acute Liver Injury in Mice , 2019, Nutrients.

[18]  T. Kusakabe,et al.  Oxytocin Suppresses Inflammatory Responses Induced by Lipopolysaccharide through Inhibition of the eIF-2α–ATF4 Pathway in Mouse Microglia , 2019, Cells.

[19]  T. Kusakabe,et al.  Pleiotropic neuroprotective effects of taxifolin in cerebral amyloid angiopathy , 2019, Proceedings of the National Academy of Sciences.

[20]  Mingxing Tang,et al.  Taxifolin Inhibits Receptor Activator of NF-κB Ligand-Induced Osteoclastogenesis of Human Bone Marrow-Derived Macrophages in vitro and Prevents Lipopolysaccharide-Induced Bone Loss in vivo , 2018, Pharmacology.

[21]  M. Akash,et al.  Taxifolin prevents postprandial hyperglycemia by regulating the activity of α‐amylase: Evidence from an in vivo and in silico studies , 2018, Journal of cellular biochemistry.

[22]  E. Tsochatzis,et al.  Non-alcoholic fatty liver disease and the interface between primary and secondary care. , 2018, The lancet. Gastroenterology & hepatology.

[23]  K. Tsuchiya,et al.  Canagliflozin, an SGLT2 inhibitor, attenuates the development of hepatocellular carcinoma in a mouse model of human NASH , 2018, Scientific Reports.

[24]  Masato Tanaka,et al.  CD11c+ resident macrophages drive hepatocyte death-triggered liver fibrosis in a murine model of nonalcoholic steatohepatitis. , 2017, JCI insight.

[25]  R. Kalaria,et al.  Taxifolin inhibits amyloid-β oligomer formation and fully restores vascular integrity and memory in cerebral amyloid angiopathy , 2017, Journal of the Neurological Sciences.

[26]  Won-Young Lee,et al.  Exendin-4 Inhibits Hepatic Lipogenesis by Increasing β-Catenin Signaling , 2016, PloS one.

[27]  Ping Yang,et al.  Detection of 191 Taxifolin Metabolites and Their Distribution in Rats Using HPLC-ESI-IT-TOF-MSn , 2016, Molecules.

[28]  P. Zhu,et al.  Dihydroquercetin (DHQ) ameliorated concanavalin A-induced mouse experimental fulminant hepatitis and enhanced HO-1 expression through MAPK/Nrf2 antioxidant pathway in RAW cells. , 2015, International Immunopharmacology.

[29]  Heng Zhou,et al.  Taxifolin protects against cardiac hypertrophy and fibrosis during biomechanical stress of pressure overload. , 2015, Toxicology and applied pharmacology.

[30]  Y. Inagaki,et al.  Macrophage-inducible C-type lectin underlies obesity-induced adipose tissue fibrosis , 2014, Nature Communications.

[31]  S. Terai,et al.  Hepatic Crown-Like Structure: A Unique Histological Feature in Non-Alcoholic Steatohepatitis in Mice and Humans , 2013, PloS one.

[32]  A. Rissanen,et al.  Blunted metabolic responses to cold and insulin stimulation in brown adipose tissue of obese humans , 2013, Obesity.

[33]  K. Yasuda,et al.  Production of functional classical brown adipocytes from human pluripotent stem cells using specific hemopoietin cocktail without gene transfer. , 2012, Cell metabolism.

[34]  S. Clarke,et al.  Activation of thermogenesis in brown adipose tissue and dysregulated lipid metabolism associated with cancer cachexia in mice. , 2012, Cancer research.

[35]  W. D. van Marken Lichtenbelt,et al.  A role of active brown adipose tissue in cancer cachexia? , 2012, Oncology reviews.

[36]  S. Terai,et al.  Melanocortin 4 receptor-deficient mice as a novel mouse model of nonalcoholic steatohepatitis. , 2011, The American journal of pathology.

[37]  A. Carpentier,et al.  Outdoor temperature, age, sex, body mass index, and diabetic status determine the prevalence, mass, and glucose-uptake activity of 18F-FDG-detected BAT in humans. , 2011, The Journal of clinical endocrinology and metabolism.

[38]  H. Tilg,et al.  Evolution of inflammation in nonalcoholic fatty liver disease: The multiple parallel hits hypothesis , 2010, Hepatology.

[39]  M. Miyagawa,et al.  High Incidence of Metabolically Active Brown Adipose Tissue in Healthy Adult Humans , 2009, Diabetes.

[40]  E. Palmer,et al.  Identification and importance of brown adipose tissue in adult humans. , 2009, The New England journal of medicine.

[41]  F. Villarroya,et al.  Brown adipose tissue as a secretory organ , 2017, Nature Reviews Endocrinology.

[42]  Chieh-fu Chen,et al.  Taxifolin ameliorates cerebral ischemia-reperfusion injury in rats through its anti-oxidative effect and modulation of NF-kappa B activation. , 2006, Journal of biomedical science.